Please ensure Javascript is enabled for purposes of website accessibility

Why AbbVie's Stock Cratered in October

By George Budwell - Nov 12, 2018 at 8:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AbbVie's stock hit bargain-basement territory last month. Here's why.

What happened

AbbVie (ABBV 1.93%), a large-cap Dividend Aristocrat, saw its shares lose an eye-popping 18.1% of their value over the course of October, according to S&P Global Market Intelligence. Why did investors run for cover?

Despite an exceptionally strong year for the drugmaker in terms of both earnings and progress on the clinical front, AbbVie simply couldn't shake off the market's dire outlook toward biopharma in general last month. The underlying reason is the growing concern among investors that President Trump's trade war with China will ultimately result in lower profits for the industry as a whole. 

Downward pointing red arrows hitting and breaking a solid surface.

Image source: Getty Images.

So what

AbbVie's shares were hit particularly hard in October because the company is in the process of trying to reassure investors about its long-term growth outlook. The backstory is that AbbVie's flagship arthritis medication Humira is set to start facing biosimilar competition (copycat drugs) in Europe soon, which has been weighing on the drugmaker's stock for the better part of 2018. 

Now what

Is AbbVie's stock now a bargain? At 10 times forward-looking earnings, bargain hunters may indeed want to snap up some shares of this top-notch biopharma stock soon. Since becoming an independent entity in 2013, AbbVie has raised its dividend at one of the fastest rates in the industry, and has outpaced most of its peers in terms of top-line growth as well. And with several new products like the endometriosis pain medication Orilissa coming, AbbVie should be able to continue delivering impress levels of top-line growth and income for investors for a long time to come. 


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
$152.34 (1.93%) $2.89

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.